Welcome to Targanta Therapeutics Print Page
Tom Parr, Ph.D.
Chief Scientific Officer

Dr Parr joined Targanta as Chief Scientific Officer in January 2005. Prior to that, Dr. Parr has been at Lilly Research Laboratories for ten years and also with several other anti-infective companies including Microcide, Intrabiotics, Embiosis, and most recently Adaptive Therapeutics where he was Vice President of Research. He has been involved in the development of several marketed and late-stage clinical candidates for both antibacterial and antifungal applications. Dr. Parr received his Ph.D. degree from The University of Calgary. He was a postdoctoral fellow at The University of British Columbia, and a member of the faculty at The University of Ottawa before beginning his industrial career.